IL1B and familial Mediterranean fever: Similarly, adverse events were also more frequent in FMF patients receiving anti-IL1 therapy than in those receiving colchicine alone: 82% vs. 74%, respectively, for local adverse events and 73% vs. 59% for systemic adverse events [50].